Company is well positioned and PTX-200 1b breast cancer trial data cannot be too far from being announced? It was mentioned under key quarterly activities that the last patient 17 has been dosed:-
Progress continues on the PTX-200 breast cancer trial, with the last patient (patient 17) has been being dosed in the escalation stage of its Akt inhibition Phase 1b breast cancer trial.
Given patient 1 was dosed (I believe) somewhere around late November / early December 2015 & the trials are open natured the data for the majority of 1b patients would be known to PTX. I suspect this is the case as it was stated in the most recent newsletter with respect to PTX-200 compelling evidence for the upcoming 1b AML trial:-
Lessons from other trials currently running? • In current Phase 1b breast cancer trial for PTX-200, interim analysis showed encouraging efficacy (including biomarker data).
Reading between the lines it would appear the data will be very positive for PTX-200.
I cannot wait to see how this unfolds over the next few months, my guess is a re-rating of the SP like no other and GLTASH
PTX Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
